Invasive Fungal Diseases in Hospitalized Patients with COVID-19 in Israel: A Multicenter Cohort Study
Authors:
- Meital ElbazMEMeital Elbaz
- Maya KoremMKMaya Korem
- Oshrat AyalonOAOshrat Ayalon
- Yonit Wiener-WellYWYonit Wiener-Well
- Yael Shachor-MeyouhasYael Shachor-Meyouhas
- Regev CohenRCRegev Cohen
- Jihad BisharaJBJihad Bishara
- Alaa AtamnaAAAlaa Atamna
- Tal Brosh-NissimovTBTal Brosh-Nissimov
- Nir MaaraviNMNir Maaravi
- Lior NesherLNLior Nesher
- Bibiana ChazanBCBibiana Chazan
Open Access
- 9 July 2022
- journal article
- research article
- Published by MDPI AG in Journal of Fungi
- Vol. 8 (7) , 721
Abstract
Highly variable estimates of COVID-19-associated fungal diseases (IFDs) have been reported. We aimed to determine the incidence of clinically important fungal diseases in hospitalized COVID-19 patients during the first year of the pandemic. We performed a multicenter survey of IFDs among patients hospitalized with COVID-19 in 13 hospitals in Israel between February 2020 and May 2021. COVID-19-associated pulmonary mold disease (PMD) and invasive candidiasis (IC) were defined using ECMM/ISHAM and EORTC/MSG criteria, respectively. Overall rates of IC and PMD among patients with critical COVID-19 were 10.86 and 10.20 per 1000 admissions, respectively, with significant variability among medical centers. PMD rates were significantly lower in centers where galactomannan was a send-out test versus centers with on-site testing (p = 0.035). The 30-day mortality rate was 67.5% for IC and 57.5% for PMD. Treatment with an echinocandin for IC or an extended-spectrum azole for PMD was associated with significantly lower mortality rates (adjusted hazard ratio [95% confidence interval], 0.26 [0.07–0.91] and 0.23 [0.093–0.57], respectively). In this multicenter national survey, variable rates of PMD were associated with on-site galactomannan testing, suggesting under-detection in sites lacking this capacity. COVID-19-related IFDs were associated with high mortality rates, which were reduced with appropriate antifungal therapy.Keywords
This publication has 28 references indexed in Scilit:
- Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidanceThe Lancet Infectious Diseases, 2021
- COVID-19–Associated Pulmonary Aspergillosis, March–August 2020Emerging Infectious Diseases, 2021
- Aspergillosis Complicating Severe Coronavirus DiseaseEmerging Infectious Diseases, 2021
- Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumoniaRadiology Case Reports, 2020
- A National Strategy to Diagnose Coronavirus Disease 2019–Associated Invasive Fungal Disease in the Intensive Care UnitClinical Infectious Diseases, 2020
- Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research ConsortiumClinical Infectious Diseases, 2019
- Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU projectCritical Care, 2019
- Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort studyThe Lancet Respiratory Medicine, 2018
- Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study*Critical Care Medicine, 2011
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987